In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
The number of ISA millionaires is growing all the time and guess what? They're really into blue-chip dividend shares listed ...
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
Sri Lanka’s leading e-commerce platform, Daraz, has officially launched its annual 11.11 shopping festival, known as the ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, ...
Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback